January 8, 2016
Agilvax Inc., a biotechnology company that develops novel vaccines and cancer immunotherapies, announced today that Dr. Federica Pericle, President & CEO, and Michael Perrine, Director of Business Development will be representing Agilvax during the 34th Annual J.P. Morgan Healthcare Conference and the 8th Annual Biotech Showcase Conference in San Francisco, CA January 11-14, 2016. Agilvax welcomes the opportunity to discuss the Company’s novel vaccine and immunotherapy discovery and development platform and pipeline products during these events.
Agilvax (www.agilvax.com) is a biotechnology company that is developing targeted vaccines and immunotherapies based on a proprietary virus-like particle (VLP) platform technology. The technology integrates epitope identification and immunogenic presentation of epitopes in a single platform. Agilvax is advancing vaccines targeting HPV, RSV, malaria, and ebola and cancer immunotherapies targeting breast cancer, metastatic disease, and immune checkpoints. The Company was founded in 2011 and has headquarters in Albuquerque, NM, USA.
Federica Pericle, PhD, MBA
President and CEO
Michael Perrine, MS, MBA
Director of Business Development